抗血管生成疗法在肝纤维化肝硬化和肝细胞癌中的应用进展  

Progress of Anti-angiogenic Therapy in Liver Fibrosis,Cirrhosis and Hepatocellular Carcinoma

作　　者：辜群利 李晖[1] 陈婧[1] GU Qunli;LI Hui;CHEN Jin(Central Laboratory,Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China;School of Clinical Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 610072,China)

机构地区：[1]成都中医药大学附属医院中心实验室,成都610072 [2]成都中医药大学临床医学院,成都610072

出　　处：《医药导报》2022年第1期92-98,共7页Herald of Medicine

基　　金：四川省科技厅项目资助(2020YFS0379)。

摘　　要：缺氧和持续性炎症刺激病理性血管生成。病理性血管生成是肝纤维化、肝硬化或肝细胞癌发生和发展过程中最重要的病理因素之一。该文探讨肝纤维化向肝硬化、肝细胞癌进展过程中,病理性新生血管生成的特点及差异,并概述酪氨酸激酶抑制药、单克隆抗体、中药方剂或单味中药及其他抗血管生成药物在这三个阶段中的应用。Hypoxia and sustained inflammation stimulate pathological angiogenesis,which is the crucial elements resulting in liver fibrosis,cirrhosis and hepatocellular carcinoma(HCC).The purpose of this paper is to investigate the characteristics and differences of pathological neovascularization in the progression of hepatic fibrosis to cirrhosis and HCC,to summarize the application of tyrosine kinase inhibitors,monoclonal antibodies,traditional Chinese medicine prescriptions or single traditional Chinese medicine and other antiangiogenesis drugs in these three stages.

关 键 词：抗血管生成疗法 肝纤维化 肝硬化 肝细胞癌 

分 类 号：R979.1[医药卫生—药品] R969[医药卫生—药学]